These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 698913)

  • 61. [Treatment of Kahler's disease].
    Foa J; Carcassonne Y
    Sem Hop; 1976 Jan; 52(3):165-71. PubMed ID: 186874
    [No Abstract]   [Full Text] [Related]  

  • 62. Prognosis of myelomatosis on treatment with prednisone and cytostatics.
    Hansen OP; Jessen B; Videbaek A
    Scand J Haematol; 1973; 10(4):282-90. PubMed ID: 4764610
    [No Abstract]   [Full Text] [Related]  

  • 63. Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB.
    Harley JB; Pajak TF; McIntyre OR; Kochwa S; Cooper MR; Coleman M; Cuttner J
    Blood; 1979 Jul; 54(1):13-22. PubMed ID: 444661
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effective treatment of advanced multiple myeloma refractory to alkylating agents.
    Barlogie B; Smith L; Alexanian R
    N Engl J Med; 1984 May; 310(21):1353-6. PubMed ID: 6546971
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
    Frei E; Schabel FM; Goldin A
    Cancer Res; 1974 Jan; 34(1):184-93. PubMed ID: 4520419
    [No Abstract]   [Full Text] [Related]  

  • 66. Results and further perspectives of plasmocytoma chemotherapy.
    Sakalová A; Hrubisko M; Gazová S; Steruská M; Prümmerová J
    Neoplasma; 1986; 33(2):251-8. PubMed ID: 3520353
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults.
    MacLennan IC; Chapman C; Dunn J; Kelly K
    Lancet; 1992 Jan; 339(8787):200-5. PubMed ID: 1346171
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Amphotericin B plus 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC no. 409962) in advanced cancer. Phase I and preliminary phase II results.
    Presant CA; Klahr C; Olander J; Gatewood D
    Cancer; 1976 Nov; 38(5):1917-21. PubMed ID: 991105
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Therapy of multiple myeloma. Italian Multiple Myeloma Study Group.
    Boccadoro M; Avvisati G; Cantonetti M; Cavo-Comotti BM; Frieri R; Gallamini A; Gallone G; Lauta VM; Liberati M; Marmont F
    Pathol Biol (Paris); 1990 Oct; 38(8):829. PubMed ID: 2274374
    [No Abstract]   [Full Text] [Related]  

  • 70. [Monoclonal gammapathy of indeterminate origin and myeloma].
    Bury J; Salmon J; Fillet G
    Rev Med Liege; 1988 Apr; 43(8):270-4. PubMed ID: 3285431
    [No Abstract]   [Full Text] [Related]  

  • 71. Vincristine, prednisone and L-asparaginase in the induction of remission in children with acute lymphoblastic leukemia following relapse.
    Kung FH; Nythan WL; Cuttner J; Falkson G; Lanzkowsky P; Del Duca V; Nawabi IU; Koch K; Pluess H; Freeman A; Burgert EO; Leone LA; Ruymann F; Patterson RB; Degnan T; Hakami N; Pajak TF; Holland J
    Cancer; 1978 Feb; 41(2):428-34. PubMed ID: 272945
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A new basis for treatment of multiple myeloma.
    Salmon SE; Durie BG; Hamburger AW
    Schweiz Med Wochenschr; 1978 Oct; 108(41):1568-72. PubMed ID: 694483
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prednisone pulse therapy for refractory myeloma.
    Alexanian R; Yap BS; Bodey GP
    Blood; 1983 Sep; 62(3):572-7. PubMed ID: 6882916
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
    Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
    Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
    [No Abstract]   [Full Text] [Related]  

  • 75. Vincristine and prednisone prolong the survival of patients receiving intravenous or oral melphalan for multiple myeloma: Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; Kochwa S; McIntyre OR; Glowienka LP; Brunner K; Rafla S; Coleman M; Cooper MR; Henderson E
    J Clin Oncol; 1988 Sep; 6(9):1481-90. PubMed ID: 3047338
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment of histiocytic and mixed lymphomas: a comparison of two, three and four drug chemotherapy.
    Lenhard RE; Ezdinli EZ; Costello W; Bennett JM; Horton J; Amorisi EL; Stolbach L; Wolter J
    Cancer; 1978 Jul; 42(1):41-52. PubMed ID: 352507
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cross-resistance to alkylating agents in multiple myeloma.
    Bladé J; Feliú E; Rozman C; Estapé J; Millá A; Montserrat E
    Cancer; 1983 Sep; 52(5):786-9. PubMed ID: 6871821
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma.
    Wilson K; Shelley W; Belch A; Brandes L; Bergsagel D; Klimo P; White D; Willan A
    Cancer Treat Rep; 1987 Oct; 71(10):981-2. PubMed ID: 3652060
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Vindesine in refractory multiple myeloma.
    van der Lelie H; Monasch E; Pegels HG; von dem Borne AE
    Cancer; 1986 Jan; 57(2):226-9. PubMed ID: 3942957
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Treatment of multiple myeloma in elderly people: long-term results in 178 patients.
    Bladé J; Muñoz M; Fontanillas M; San Miguel J; Alcalá A; Maldonado J; Besses C; Moro MJ; García-Conde J; Rozman C; Montserrat E; Estapé J
    Age Ageing; 1996 Sep; 25(5):357-61. PubMed ID: 8921139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.